奥洛他定联合卡介菌多糖核酸对慢性荨麻疹患者的免疫应答机制探讨

Mechanism of Olopatatadine combined with BCG polysaccharide nucleic acid onimmune response in patients with chronicurticaria through TLR2 pathway

目的研究奥洛他定联合卡介菌多糖核酸治疗前后慢性荨麻疹患者Toll样受体2(TLR2)表达量的变化及其与免疫球蛋白E(IgE)、补体C3、补体C4、细胞因子含量的相关性。方法选取2016年1月-2016年11月在佛山市中医院接受奥洛他定联合卡介菌多糖核酸治疗的慢性荨麻疹患者作为研究对象。治疗前和治疗后2、4及6周时,采集外周血并测定TLR2、TLR4、TLR7、TLR9的表达量,采集血清并测定IgE、C3、C4、Th1、Th2细胞因子的含量。结果治疗后2、4及6周时,外周血单个核细胞中TLR2的mRNA含量均低于治疗前,TLR4、TLR7及TLR9的mRNA含量与治疗前比较,差异无统计学意义(P>0.05);血清中IgE、白细胞介素4(IL-4)、白细胞介素10(IL-10)的含量均低于治疗前,C3、C4、IFN-γ、白细胞介素2(IL-2)的含量高于治疗前;外周血中TLR2的表达量与血清中IgE、IL-4、IL-10的含量呈正相关,与C3、C4、IFN-γ、IL-2的含量呈负相关。结论奥洛他定联合卡介菌多糖核酸治疗可能通过TLR2通路调节慢性荨麻疹患者体内的免疫应答。

Objective To study TLR2 expression in patients with chronic urticaria pre-and post-treatment of olopatatadine combined with BCG polysaccharide nucleic acid and its correlation with IgE,C3,C4 and cytokine levels.Methods Patients with chronic urticaria who received olopatatadine combined with BCG polysaccharide nucleic acid treatment in our hospital from January 2016 to November 2016 were selected as the research subjects;pre-and 2 weeks,4 weeks and 6 weeks post-treatment,peripheral blood was collected to determine expression levels of TLR2,TLR4,TLR7 and TLR9,and serum was collected to determine levels of IgE,C3,C4 and Th1 and Th2 cytokines.Results About 2 weeks,4 weeks and 6 weeks post-treatment,TLR2 mRNA levels in peripheral blood mononuclear cells were lower than those pre-treatment while TLR4,TLR7 and TLR9 mRNA levels were not significantly different from those pre-treatment,and serum IgE,IL-4 and IL-10 levels were lower than those pretreatment while C3,C4,IFN-γand IL-2 levels were higher than those pre-treatment;TLR2 expression in peripheral blood was positively correlated with serum IgE,IL-4 and IL-10 levels,and negatively correlated with C3,C4,IFN-γand IL-2 levels.Conclusion Treatment of Olopatatadine combined with BCG polysaccharide nucleic acid can regulate the immune response in patients with chronic urticaria through TLR2 pathway.